Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ovarian cancer hope: immunotherapy and targeted pill combo tested

NCT ID NCT03740165

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 20, 2026 · Updated 3 times

Summary

This large phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) and the targeted therapy olaparib (Lynparza) to standard chemotherapy helps women with advanced ovarian cancer that does not have a BRCA mutation. Over 1,300 participants received either the drug combo or placebo. The goal was to see if the combination delays cancer growth or improves survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pembrolizumab (immunotherapy) and olaparib (targeted therapy)
What this could lead to
If successful, this combination could offer a new first-line treatment option that delays cancer progression in women with advanced ovarian cancer.
What could go wrong
This is a large phase 3 trial, but results may not apply to all patients. Adding more drugs can increase side effects, and the benefit may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,367 people

The number who actually took part.

Started

Dec 2018

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has histologically confirmed International Federation of Gynecology and Obstetrics (FIGO) Stage III or Stage IV EOC (high-grade predominantly serous, endometrioid (any grade), carcinosarcoma, mixed mullerian with high-grade serous component, clear cell, or low-grade serous OC), primary peritoneal cancer, or fallopian tube cancer * Has just completed primary debulking surgery or is eligible for primary debulking surgery or is a potential candidate for interval debulking surgery * Is a candidate for carboplatin and paclitaxel chemotherapy, to be administered in the adjuvant or neoadjuvant setting * Candidates for neoadjuvant chemotherapy, has a cancer antigen 125 (CA-125) (kilounits/L):carcinoembryonic antigen (CEA; ng/mL) ratio greater than or equal to 25 * Is able to provide a newly obtained core or excisional biopsy of a tumor lesion for prospective testing of BRCA1/2 and Programmed Cell Death-Ligand 1 (PD-L1) tumor markers status prior to randomization * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, as assessed within 7 days prior to initiating chemotherapy in the lead-in period and within 3 days prior to Day 1 of Cycle 1 * Female participants are not pregnant, not breastfeeding, and at least 1 of the following conditions applies: a.) Not a woman of childbearing potential (WOCBP) OR b.) Is a WOCBP and using a contraceptive method that is highly effective, with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle, during the Treatment Period and for at least 120 days following the last dose of pembrolizumab (or pembrolizumab placebo) and bevacizumab (if administered), at least 180 days following the last dose of olaparib (or olaparib placebo), and at least 210 days following the last dose of chemotherapy and agrees not to donate eggs (ova, oocytes) to others or freeze/store for her own use for the purpose of reproduction during this period. The investigator should evaluate the potential for contraceptive method failure in relationship to the first dose of study treatment. A WOCBP must have a negative highly sensitive pregnancy test within either 24 hours (urine) or 72 hours (serum) before the first dose of study treatment. If a urine test cannot be confirmed as negative, a serum pregnancy test is required. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies * Has adequate organ function Exclusion Criteria: * Has mucinous, germ cell, or borderline tumor of the ovary * Has a known or suspected deleterious mutation (germline or somatic) in either BRCA1 or BRCA2 * Has a history of non-infectious pneumonitis that required treatment with steroids or currently has pneumonitis * Has either myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or has features suggestive of MDS/AML * Has a known additional malignancy that is progressing or has required active treatment in the last 3 years Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. ductal carcinoma in situ, cervical carcinoma in situ) that has undergone potentially curative therapy are not excluded. * Has ongoing Grade 3 or Grade 4 toxicity, excluding alopecia, following chemotherapy administered during the lead-in period * Has known active central nervous system metastases and/or carcinomatous meningitis. Participants with brain metastases may participate provided they were previously treated (except with chemotherapy) and are radiologically stable, clinically stable, and no steroids were used for the management of symptoms related to brain metastases within 14 days prior to randomization. Stable brain metastases should be established prior to the first dose of study medication lead-in chemotherapy * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (dosing \>10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization * Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs) Note: Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed. * Has a known history of active tuberculosis (TB; Bacillus Tuberculosis) * Has an active infection requiring systemic therapy * Has received colony-stimulating factors (eg, granulocyte colony stimulating factor \[G-CSF\], granulocyte macrophage colony-stimulating factor \[GM-CSF\] or recombinant erythropoietin) within 4 weeks prior to receiving chemotherapy during the lead-in period * Is considered to be of poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection * Has had surgery to treat borderline tumors, early stage EOC, or early stage fallopian tube cancer \<6 months prior to screening * Has a known history of human immunodeficiency virus (HIV) infection * Has a known history of hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] reactive) or known active hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection. Testing for hepatitis B or hepatitis C is required at screening only if mandated by local health authority. Note: Participants with a history of hepatitis B but who are HBsAg negative are eligible for the study * Is either unable to swallow orally administered medication or has a gastrointestinal (GI) disorder affecting absorption (e.g. gastrectomy, partial bowel obstruction, malabsorption) * Has uncontrolled hypertension * Has current, clinically relevant bowel obstruction (including sub-occlusive disease), abdominal fistula or GI perforation, related to underlying EOC (for participants receiving bevacizumab) * Has a history of hemorrhage, hemoptysis or active GI bleeding within 6 months prior to randomization (for participants receiving bevacizumab) * Is a WOCBP who has a positive urine pregnancy test within 72 hours before the first dose of chemotherapy in the lead-in period and within 72 hours prior to Day 1 of Cycle 1, is pregnant or breastfeeding, or is expecting to conceive children within the projected duration of the study, starting with screening through 120 days following the last dose of pembrolizumab (or pembrolizumab placebo) and bevacizumab (if administered), at least 180 days following the last dose of olaparib (or olaparib placebo), and at least 210 days following the last dose of chemotherapy * Has received prior treatment for any stage of OC, including radiation or systemic anti-cancer therapy (e.g. chemotherapy, hormonal therapy, immunotherapy, investigational therapy) * Has received prior therapy with an anti-Programmed Cell Death-1 (anti-PD-1), anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T lymphocyte antigen-4 \[CTLA-4\], OX 40, CD137) * Has received prior therapy with either olaparib or any other poly(adenosine-ribose) polymerase (PARP) inhibitor * Has intraperitoneal chemotherapy planned or has been administered as first-line therapy * Has received a live vaccine within 30 days prior to the first dose of study treatment on Day 1 of Cycle 1 * Has severe hypersensitivity (≥Grade 3) to pembrolizumab, olaparib, carboplatin, paclitaxel or bevacizumab (if using) and/or any of their excipients * Is currently receiving either strong (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate (eg, ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil) inhibitors of cytochrome P450 (CYP)3A4 that cannot be discontinued for the duration of the study * Is currently receiving either strong (e.g. phenobarbital, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine, and St John's Wort) or moderate (e.g. bosentan, efavirenz, modafinil) inducers of CYP3A4 that cannot be discontinued for the duration of the study * Is currently participating or has participated in a study of an investigational agent or has used an investigational device within 4 weeks (28 days) of starting chemotherapy in the Lead-in Period * Has resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible cardiac conditions or participant has congenital long QT syndrome * Has had an allogenic tissue/solid organ transplant, has received previous allogenic bone-marrow transplant, or has received double umbilical cord transplantation * Either has had major surgery within 3 weeks of randomization or has not recovered from any effects of any major surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epithelial ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 fallopian tube cancer fallopian tube neoplasm ovarian cancer ovarian carcinoma peritoneal neoplasm primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fallopian tube cancer Ovarian cancer Peritoneal neoplasms

Contacts and locations

Locations

  • A. Tsyb Medical Radiological Research Center ( Site 1513)

    Obninsk, Kaluzskaja Oblast, 249036, Russia

  • A.O. Univ. S. M. della Misericordia ( Site 1114)

    Udine, 33100, Italy

  • A.O.U. Citta della Salute e della Scienza di Torino ( Site 1104)

    Turin, Piedmont, 10126, Italy

  • A.O.U. Federico II di Napoli ( Site 1107)

    Naples, 80131, Italy

  • ASST Lecco. Ospedale A. Manzoni ( Site 1101)

    Lecco, 23900, Italy

  • AZ Maria Middelares Gent ( Site 0300)

    Ghent, Oost-Vlaanderen, 9000, Belgium

  • Akdeniz Universitesi Tıp Fakultesi ( Site 1901)

    Antalya, 07070, Turkey (Türkiye)

  • Ankara UTF Cebeci Arastırma ve Uygulama Hastanesi ( Site 1905)

    Ankara, 06590, Turkey (Türkiye)

  • Arkhangelsk Clinical Oncological Dispensary ( Site 1508)

    Arkhangelsk, Arkhangelskaya oblast, 163045, Russia

  • Asan Medical Center ( Site 2402)

    Seoul, 05505, South Korea

  • Azienda Ospedaliera Policlinico Umberto I ( Site 1111)

    Roma, 00161, Italy

  • Bakirkoy Sadi Konuk Egitim ve Arastirma Hastanesi ( Site 1907)

    Istanbul, 34147, Turkey (Türkiye)

  • Ballarat Health Services ( Site 2202)

    Ballarat, Victoria, 3350, Australia

  • Bialostockie Centrum Onkologii ( Site 1412)

    Bialystok, Podlaskie Voivodeship, 15-027, Poland

  • Biomelab S A S ( Site 2900)

    Barranquilla, Atlántico, 080002, Colombia

  • Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz ( Site 0802)

    Miskolc, Borsod-Abauj Zemplen county, 1051, Hungary

  • CHU de Brest -Site Hopital Morvan ( Site 0616)

    Brest, Brittany Region, 29200, France

  • CHU de Liege ( Site 0310)

    Liège, Liege, 4000, Belgium

  • CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0219)

    Montreal, Quebec, H1T 2M4, Canada

  • CIUSSS du Saguenay-Lac-St-Jean ( Site 0218)

    Chicoutimi, Quebec, G7H 5H6, Canada

  • Cairns and Hinterland Hospital and Health Service ( Site 2201)

    Cairns, Queensland, 4870, Australia

  • Cancer Care Langenhoven Drive Oncology Centre ( Site 1701)

    Port Elizabeth, Eastern Cape, 6045, South Africa

  • Cancercare ( Site 1706)

    Cape Town, Western Cape, 7700, South Africa

  • Cape Town Oncology Trials Pty Ltd ( Site 1707)

    Kraaifontein, Western Cape, 7570, South Africa

  • Caritas Klinikum Saarbruecken St. Theresia ( Site 0702)

    Saarbrücken, Saarland, 66113, Germany

  • Carmel Medical Center ( Site 1007)

    Haifa, 3436212, Israel

  • Central City Clinical Hospital ( Site 2150)

    Uzhhorod, Zakarpattia Oblast, 88000, Ukraine

  • Centre D Oncologie de Gentilly ( Site 0609)

    Nancy, Meurthe-et-Moselle, 54100, France

  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0208)

    Montreal, Quebec, H2X 0A9, Canada

  • Centre Hospitalier de l'Ardenne ( Site 0303)

    Libramont, Luxembourg, 6800, Belgium

  • Centre Paul Strauss ( Site 0615)

    Strasbourg, Bas-Rhin, 67065, France

  • Centro Investigación del Cáncer James Lind ( Site 2810)

    Temuco, Araucania, 4780000, Chile

  • Centro Medico Imbanaco de Cali S.A ( Site 2909)

    Cali, Valle del Cauca Department, 760042, Colombia

  • Centro Oncologico Antofagasta ( Site 2804)

    Antofagasta, 1240000, Chile

  • Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 2808)

    Temuco, Araucania, 4810218, Chile

  • Chaim Sheba Medical Center ( Site 1000)

    Ramat Gan, 5262000, Israel

  • Changhua Christian Hospital ( Site 2507)

    Changhua, 50006, Taiwan

  • Charite Campus Virchow-Klinikum - CVK ( Site 0700)

    Berlin, 13353, Germany

  • China Medical University Hospital ( Site 2506)

    Taichung, 40447, Taiwan

  • City Clinical Oncology Center ( Site 1505)

    Saint Petersburg, Sankt-Peterburg, 198255, Russia

  • Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 2912)

    Bogotá, Bogota D.C., 111321, Colombia

  • Clinica Universitaria de Navarra ( Site 1600)

    Madrid, 28027, Spain

  • Clinica de Pesquisas e Ctro de Estudos Onc. Ginecol. e Mamaria Ltda ( Site 2706)

    São Paulo, 01317-000, Brazil

  • Cliniques Universitaires Saint-Luc ( Site 0312)

    Brussels, Bruxelles-Capitale, Region de, 1200, Belgium

  • Complejo Hospitalario Universitario A Coruna. CHUAC ( Site 1608)

    A Coruña, La Coruna, 15006, Spain

  • Curo Oncology ( Site 1710)

    Pretoria, Gauteng, 0031, South Africa

  • Dartmouth Hitchcock Medical Center ( Site 0024)

    Lebanon, New Hampshire, 03756, United States

  • Debreceni Egyetem Klinikai Kozpont ( Site 0801)

    Debrecen, 4032, Hungary

  • Department of Medical Oncology ( Site 1703)

    Pretoria, Gauteng, 0002, South Africa

  • Disney Family Cancer Center ( Site 0042)

    Burbank, California, 91505, United States

  • Dr. Sudarshan K. Sharma, LTD ( Site 0061)

    Hinsdale, Illinois, 60521, United States

  • Edith Wolfson Medical Center ( Site 1003)

    Holon, 5822012, Israel

  • Ehime University Hospital ( Site 2600)

    Tōon, Ehime, 791-0295, Japan

  • Emory School of Medicine ( Site 0053)

    Atlanta, Georgia, 30322, United States

  • Etlik Zubeyde Hanim Kadin Hastaliklari Egitim ve Arastirma Hastanesi ( Site 1903)

    Ankara, 06050, Turkey (Türkiye)

  • FSBI National Medical Oncology Research Center n.a. N.N. Blokhina ( Site 1500)

    Moscow, Moscow, 115478, Russia

  • FSCC of Special Types of Med. Care and Technologies ( Site 1503)

    Moscow, Moscow, 115682, Russia

  • Fakultni nemocnice Brno ( Site 0404)

    Brno, Brno-mesto, 602 00, Czechia

  • Fakultni nemocnice Olomouc ( Site 0402)

    Olomouc, 779 00, Czechia

  • Fakultni nemocnice Ostrava ( Site 0403)

    Ostrava-Poruba, Moravian-Silesian Region, 708 52, Czechia

  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1115)

    Milan, 20133, Italy

  • Fundacion Arturo Lopez Perez FALP ( Site 2800)

    Santiago, Region M. de Santiago, 7500922, Chile

  • Grand Hopital de Charleroi ( Site 0302)

    Charleroi, Hainaut, 6000, Belgium

  • Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 2180)

    Kharkiv, Kharkiv Oblast, 61024, Ukraine

  • Groote Schuur Hospital ( Site 1704)

    Cape Town, Gauteng, 7925, South Africa

  • Gunma Prefectural Cancer Center ( Site 2609)

    Ōta, Gunma, 373-8550, Japan

  • Gynaekologisches Zentrum ( Site 0712)

    Bonn, North Rhine-Westphalia, 53111, Germany

  • HELIOS Klinikum Krefeld ( Site 0715)

    Krefeld, North Rhine-Westphalia, 47805, Germany

  • Hemato Oncologos S.A. ( Site 2906)

    Cali, Valle del Cauca Department, 760042, Colombia

  • Hillel Yaffe Medical Center ( Site 1011)

    Hadera, 3810101, Israel

  • Hokkaido University Hospital ( Site 2607)

    Sapporo, Hokkaido, 060-8648, Japan

  • Holy Name Medical Center ( Site 0037)

    Teaneck, New Jersey, 07666, United States

  • Hopital Prive Jean Mermoz ( Site 0607)

    Lyon, Auvergne, 69008, France

  • Hopital Tenon ( Site 0612)

    Paris, 75020, France

  • Hopital de la Timone ( Site 0617)

    Marseille, Bouches-du-Rhone, 13005, France

  • Hospital Araujo Jorge Associacao de Combate ao Cancer de Goias ( Site 2708)

    Goiânia, Goiás, 74605-070, Brazil

  • Hospital Bruno Born ( Site 2704)

    Lajeado, Rio Grande do Sul, 95900-000, Brazil

  • Hospital Erasto Gaertner ( Site 2716)

    Curitiba, Paraná, 82520-060, Brazil

  • Hospital General Universitario de Valencia ( Site 1610)

    Valencia, Valenciana, Comunitat, 46014, Spain

  • Hospital Nossa Senhora Da Conceicao ( Site 2703)

    Porto Alegre, Rio Grande do Sul, 91350-200, Brazil

  • Hospital Provincial San Pedro de Alcantara ( Site 1607)

    Cáceres, 10003, Spain

  • Hospital Universitario Lucus Augusti ( Site 1609)

    Lugo, 27003, Spain

  • Hospital Universitario Virgen del Rocio ( Site 1604)

    Seville, 41013, Spain

  • Hospital Universitario de Donostia ( Site 1602)

    Donostia / San Sebastian, Gipuzkoa, 20014, Spain

  • Hospital de Caridade de Ijui ( Site 2712)

    Ijuí, Rio Grande do Sul, 98700-000, Brazil

  • Hospital de Terrassa ( Site 1606)

    Terrassa, Barcelona, 08227, Spain

  • IRCCS Giovanni Paolo II. Ospedale Oncologico ( Site 1108)

    Bari, Abruzzo, 70124, Italy

  • Imelda Ziekenhuis Bonheiden ( Site 0301)

    Bonheiden, Antwerpen, 1932, Belgium

  • Institut Gustave Roussy ( Site 0600)

    Villejuif, Val-de-Marne, 94800, France

  • Institut de Cancerologie Lucien Neuwirth ( Site 0613)

    Saint-Priest-en-Jarez, Pays de la Loire Region, 42270, France

  • Institut de Cancerologie du Gard - CHU Caremeau ( Site 0610)

    Nîmes, Gard, 30029, France

  • Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 1603)

    L'Hospitalet de Llobregat, Barcelona, 08909, Spain

  • Instituto Nacional de Cancer Hospital do Cancer II ( Site 2700)

    Rio de Janeiro, 20220-410, Brazil

  • Instituto Nacional de Cancerologia E.S.E ( Site 2910)

    Bogotá, Bogota D.C., 110321, Colombia

  • Instituto Valenciano de Oncologia ( Site 1601)

    Valencia, Valenciana, Comunitat, 46009, Spain

  • Instituto do Cancer do Ceara ( Site 2707)

    Fortaleza, Ceará, 60430-230, Brazil

  • Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 2714)

    São Paulo, 01246-000, Brazil

  • Iram Cancer Research ( Site 2809)

    Santiago, Region M. de Santiago, 7630370, Chile

  • Istanbul Acibadem University Atakent Hospital ( Site 1902)

    Küçükçekmece, Istanbul, 34303, Turkey (Türkiye)

  • Istanbul Universitesi Istanbul Tip Fakultesi ( Site 1900)

    Istanbul, 34093, Turkey (Türkiye)

  • Istituto Europeo di Oncologia ( Site 1100)

    Milan, Lombardy, 20141, Italy

  • Istituto Oncologico Veneto IRCCS ( Site 1113)

    Padova, Veneto, 35128, Italy

  • Iwate Medical University Hospital ( Site 2606)

    Shiwa-gun, Iwate, 028-3695, Japan

  • Jessa Ziekenhuis ( Site 0309)

    Hasselt, Limburg, 3500, Belgium

  • Kagoshima City Hospital ( Site 2612)

    Kagoshima, 890-8760, Japan

  • Kaiser Permanente N. CA Regional Oncology Clinical Trials ( Site 0008)

    Vallejo, California, 94589, United States

  • Kaiser Permanente Oncology Clinical Trial - San Francisco ( Site 0078)

    San Francisco, California, 94115, United States

  • Kaiser Permanente Oncology Clinical Trial - Santa Clara ( Site 0079)

    Santa Clara, California, 95051, United States

  • Kaiser Permanente Oncology Clinical Trial - Walnut Creek ( Site 0080)

    Walnut Creek, California, 94596, United States

  • Kaiser Permanente Oncology Clinical Trial -Oakland ( Site 0077)

    Oakland, California, 94611, United States

  • Kaiser Permanente Oncology Clinical Trials-Roseville ( Site 0084)

    Roseville, California, 95661, United States

  • Kaiser Permanente Oncology Clinical Trials-Sacramento ( Site 0083)

    Sacramento, California, 95814, United States

  • Kingston Health Sciences Centre ( Site 0207)

    Kingston, Ontario, K7L 2V7, Canada

  • Klinikum Chemnitz gGmbH ( Site 0711)

    Chemnitz, Saxony, 09116, Germany

  • Klinikum Dortmund gGmbH ( Site 0717)

    Dortmund, North Rhine-Westphalia, 44137, Germany

  • Klinikum Rechts der Isar. Technischen Universitaet Muenchen ( Site 0710)

    Munich, Bavaria, 72074, Germany

  • Kyiv City Clinical Oncological Center ( Site 2140)

    Kyiv, 03115, Ukraine

  • Kyorin University Hospital ( Site 2610)

    Mitaka, Tokyo, 181-8611, Japan

  • Linkou Chang Gung Memorial Hospital ( Site 2501)

    Taoyuan, 333, Taiwan

  • Little Company of Mary Hospital ( Site 1700)

    Pretoria, Gauteng, 0181, South Africa

  • Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 2170)

    Lviv, Lviv Oblast, 79031, Ukraine

  • MD Anderson Cancer Center at Cooper ( Site 0067)

    Camden, New Jersey, 08103, United States

  • MEDICAL COLLEGE OF WISCONSIN ( Site 0064)

    Milwaukee, Wisconsin, 53226, United States

  • MI Odessa Regional Oncological Centre ( Site 2121)

    Odesa, Odesa Oblast, 65055, Ukraine

  • MI Precarpathian Clinical Oncology Center ( Site 2181)

    Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76018, Ukraine

  • MacKay Memorial Hospital ( Site 2500)

    Taipei, 10449, Taiwan

  • Marienhospital Stuttgart Vincenz von Paul Kliniken gGmbH ( Site 0707)

    Stuttgart, Baden-Wurttemberg, 70199, Germany

  • Medical Rehabilitation Center ( Site 1502)

    Moscow, Moscow, 125367, Russia

  • Medipol Universite Hastanesi ( Site 1909)

    Istanbul, 34214, Turkey (Türkiye)

  • Memorial Health University Medical Center ( Site 0011)

    Savannah, Georgia, 31404, United States

  • Miami Valley Hospital [Dayton, OH] ( Site 0073)

    Centerville, Ohio, 45459, United States

  • Monash Health ( Site 2204)

    Clayton, Victoria, 3168, Australia

  • Municipal non-profit Enterprise Khmelnytskyi Regional Antitu-Gynecological Oncology department, Poli

    Khmelnytskyi, Khmelnytskyi Oblast, 29009, Ukraine

  • Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 1406)

    Gliwice, Silesian Voivodeship, 44-102, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • National Cancer Center Hospital ( Site 2605)

    Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East ( Site 2602)

    Kashiwa, Chiba, 277-8577, Japan

  • National Cheng Kung University Hospital ( Site 2508)

    Tainan, 704, Taiwan

  • National Defense Medical College Hospital ( Site 2608)

    Tokorozawa, Saitama, 359-8513, Japan

  • National Hospital Organization Shikoku Cancer Center ( Site 2601)

    Matsuyama, Ehime, 791-0280, Japan

  • National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 1504)

    Saint Petersburg, Sankt-Peterburg, 197758, Russia

  • National Taiwan University Hospital ( Site 2502)

    Taipei, 10002, Taiwan

  • Nebraska Methodist Hospital ( Site 0063)

    Omaha, Nebraska, 68114, United States

  • Nemocnice Na Bulovce ( Site 0401)

    Prague, Praha, Hlavni Mesto, 180 81, Czechia

  • Niigata Cancer Center Hospital ( Site 2618)

    Niigata, 951-8566, Japan

  • Northeast Georgia Medical Center ( Site 0029)

    Gainesville, Georgia, 30501, United States

  • Northwell Health- Monter Cancer Center ( Site 0075)

    Lake Success, New York, 11042, United States

  • OSU Wexner Medical Center ( Site 0076)

    Hilliard, Ohio, 43026, United States

  • Oncocentro ( Site 2801)

    Viña del Mar, Valparaiso, 2520598, Chile

  • Oncology/Hematology Care Clinical Trials, LLC ( Site 8001)

    Cincinnati, Ohio, 45242, United States

  • Oncomedica S.A. ( Site 2911)

    Montería, Departamento de Córdoba, 230002, Colombia

  • Orszagos Onkologiai Intezet ( Site 0800)

    Budapest, 1122, Hungary

  • Osaka International Cancer Institute ( Site 2617)

    Osaka, 541-8567, Japan

  • Ospedale Cannizzaro ( Site 1110)

    Catania, 95126, Italy

  • Outeniqua Cancercare Oncology Unit ( Site 1708)

    George, Western Cape, 6530, South Africa

  • Parkland Hospital ( Site 0081)

    Dallas, Texas, 75235, United States

  • Pecsi Tudomanyegyetem Klinikai Kozpont ( Site 0805)

    Pécs, Baranya, 7624, Hungary

  • Policlinico Universitario Gemelli ( Site 1105)

    Roma, 00168, Italy

  • Pontificia Universidad Catolica de Chile ( Site 2805)

    Santiago, Region M. de Santiago, 8330032, Chile

  • Presidio Ospedaliero Santa Chiara ( Site 1109)

    Trento, 38122, Italy

  • Princess Margaret Hospital.. ( Site 0202)

    Toronto, Ontario, M5G 2M9, Canada

  • RMI - Sumy Regional Clinical Oncology Dispensary ( Site 2191)

    Sumy, Sumska Oblast, 40022, Ukraine

  • Rabin Medical Center ( Site 1004)

    Petah Tikva, 4941492, Israel

  • Rambam Medical Center ( Site 1002)

    Haifa, 3525408, Israel

  • Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 2710)

    São Paulo, 01321-001, Brazil

  • Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1507)

    Ufa, Baskortostan, Respublika, 450054, Russia

  • Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1509)

    Kazan', Tatarstan, Respublika, 420029, Russia

  • Royal Victoria Hospital McGill University Health Centre ( Site 0211)

    Montreal, Quebec, H4A 3J1, Canada

  • Rush University Medical Center ( Site 0019)

    Chicago, Illinois, 60612, United States

  • Sacro Cuore di Gesu Fatebenefratelli ( Site 1112)

    Benevento, 82100, Italy

  • Saint Dominic - Jackson Memorial Hospital ( Site 0072)

    Jackson, Mississippi, 39216, United States

  • Saint Vincent Hospital and Health Center ( Site 0012)

    Indianapolis, Indiana, 46260, United States

  • Saitama Cancer Center ( Site 2614)

    Kitaadachi-gun, Saitama, 362-0806, Japan

  • Saitama Medical University International Medical Center ( Site 2604)

    Hidaka, Saitama, 350-1298, Japan

  • Sakarya Universitesi Tip Fakultesi Hastanesi ( Site 1906)

    Sakarya, 54290, Turkey (Türkiye)

  • Samsung Medical Center ( Site 2401)

    Seoul, 06351, South Korea

  • Sandton Oncology Medical Group PTY LTD ( Site 1712)

    Sandton, Gauteng, 2196, South Africa

  • Sanford Gynecology Oncology ( Site 0004)

    Sioux Falls, South Dakota, 57104, United States

  • Sanford Roger Maris Cancer Center ( Site 0082)

    Fargo, North Dakota, 58122, United States

  • Sarasota Memorial Hospital ( Site 0023)

    Sarasota, Florida, 34239, United States

  • Seoul National University Bundang Hospital ( Site 2404)

    Seongnam-si, Kyonggi-do, 13620, South Korea

  • Seoul National University Hospital ( Site 2403)

    Seoul, 03080, South Korea

  • Severance Hospital Yonsei University Health System ( Site 2400)

    Seoul, 03722, South Korea

  • Shaare Zedek Medical Center ( Site 1005)

    Jerusalem, 9103102, Israel

  • Smilow Cancer Center at Yale-New Haven ( Site 0057)

    New Haven, Connecticut, 06511, United States

  • Sociedad Oncovida S.A. ( Site 2807)

    Santiago, Region M. de Santiago, 7510032, Chile

  • Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 2913)

    Valledupar, Cesar Department, 200001, Colombia

  • Soroka Medical Center ( Site 1006)

    Beersheba, 8410101, Israel

  • Sourasky Medical Center ( Site 1001)

    Tel Aviv, 6423906, Israel

  • St George Hospital ( Site 2207)

    Kogarah, New South Wales, 2217, Australia

  • St. Marianna University School of Medicine Hospital ( Site 2613)

    Kawasaki, Kanagawa, 216-8511, Japan

  • Staedtisches Krankenhaus Kiel GmbH ( Site 0709)

    Kiel, Schleswig-Holstein, 24116, Germany

  • Sunshine Hospital. ( Site 2205)

    St Albans, Victoria, 3021, Australia

  • Swietokrzyskie Centrum Onkologii SPZOZ ( Site 1410)

    Kielce, Świętokrzyskie Voivodeship, 25-734, Poland

  • Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu Medycznego im. K. Marcinkowskiego w Pozna

    Poznan, Greater Poland Voivodeship, 61-848, Poland

  • Szpitale Pomorskie Sp. z o.o. ( Site 1407)

    Gdynia, Pomeranian Voivodeship, 81-519, Poland

  • Taichung Veterans General Hospital ( Site 2510)

    Taichung, 40705, Taiwan

  • Taipei Veterans General Hospital ( Site 2503)

    Taipei, 11217, Taiwan

  • Texas Oncology, P.A. - Bedford ( Site 8005)

    Bedford, Texas, 76022, United States

  • Texas Oncology, P.A. Texas Oncology-Tyler ( Site 8006)

    Tyler, Texas, 75702, United States

  • Texas Oncology-Dallas Presbyterian Hospital ( Site 8004)

    Dallas, Texas, 75231, United States

  • The Bing Cancer Center ( Site 0044)

    Columbus, Ohio, 43214, United States

  • The Credit Valley Hospital ( Site 0206)

    Mississauga, Ontario, L5M 2N1, Canada

  • The Oncology Centre ( Site 1709)

    Durban, KwaZulu-Natal, 4091, South Africa

  • Tom Baker Cancer Centre ( Site 0200)

    Calgary, Alberta, T2N 4N2, Canada

  • UT Southwestern Medical Center ( Site 0046)

    Dallas, Texas, 75390, United States

  • UZ Gent ( Site 0307)

    Ghent, Oost-Vlaanderen, 9000, Belgium

  • UZ Leuven Campus Gasthuisberg ( Site 0306)

    Leuven, Antwerpen, 3000, Belgium

  • Uludag Universitesi Tip Fakultesi ( Site 1904)

    Bursa, 16059, Turkey (Türkiye)

  • Uniklinik RWTH Aachen ( Site 0718)

    Aachen, North Rhine-Westphalia, 52074, Germany

  • Universitaetsklinikum Duesseldorf ( Site 0704)

    Düsseldorf, North Rhine-Westphalia, 40225, Germany

  • Universitaetsklinikum Muenster ( Site 0720)

    Münster, North Rhine-Westphalia, 48149, Germany

  • University of Alabama at Birmingham (UAB) ( Site 0036)

    Birmingham, Alabama, 35233, United States

  • University of Arizona Cancer Center ( Site 0074)

    Tucson, Arizona, 85719, United States

  • University of Chicago ( Site 0049)

    Chicago, Illinois, 60637, United States

  • University of Iowa Hospital and Clinics ( Site 0005)

    Iowa City, Iowa, 52242, United States

  • University of Kentucky ( Site 0045)

    Lexington, Kentucky, 40536, United States

  • University of the Ryukyus Hospital ( Site 2616)

    Nakagami-gun, Okinawa, 903-0215, Japan

  • Uzsoki Utcai Korhaz ( Site 0803)

    Budapest, 1145, Hungary

  • Virginia Cancer Specialists, PC ( Site 8003)

    Gainesville, Virginia, 20155, United States

  • Vseobecna fakultni nemocnice v Praze ( Site 0400)

    Prague, Praha, Hlavni Mesto, 120 00, Czechia

  • Washington University - School of Medicine ( Site 0062)

    St Louis, Missouri, 63110, United States

  • Weinberg Cancer Institute at Franklin Square ( Site 0035)

    Baltimore, Maryland, 21237, United States

  • Wilgers Oncology Centre ( Site 1705)

    Pretoria, Gauteng, 0081, South Africa

  • Wits Clinical Research ( Site 1702)

    Johannesburg, Gauteng, 2193, South Africa

  • Women and Infants Hospital [Providence, RI] ( Site 0039)

    Providence, Rhode Island, 02905, United States

  • Xarxa Assistencial Universitaria Manresa ( Site 1605)

    Manresa, Barcelona, 08243, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.